Technology News and Research

RSS

Histone modifications associated with pancreatic cancer development and progression

Specific chemical modifications to proteins called histones, which are found in the nucleus of cells and act as spools around which DNA is wound, can be used to predict prognosis and response to treatment in subsets patients with pancreatic cancer, a study by researchers at UCLA's Jonsson Comprehensive Cancer Center has found.

12 Feb 2010

Gold nanoparticles for cancer treatment

World Gold Council (WGC) has today published 'Gold for Good: Gold and nanotechnology in the age of innovation', a research paper detailing new scientific and technological innovations using gold. The report, which was produced in conjunction with Cientifica Ltd, the world's leading source of global business and investor intelligence about nanotechnologies, demonstrates how gold nanoparticles offer the potential to overcome many of the serious issues facing mankind over the coming decades.

12 Feb 2010

World leaders need to alter their notions on sustainable agriculture to prevent starvation catastrophe

Yields from some of the most important crops begin to decline sharply when average temperatures exceed about 30 degrees Celsius, or 86 Fahrenheit. Projections are that by the end of this century much of the tropics and subtropics will regularly see growing season temperatures above that level, hotter than the hottest summers now on record.

12 Feb 2010

Healthcare thought leaders and experts to meet in MCEG 2010 Annual Forum

The Managed Care Executive Group has gathered some of healthcare's most distinguished thought leaders and experts on healthcare reform to meet March 21-24 in Fort Lauderdale Florida for their Annual Forum entitled "Reform + Evolution = Revolution".

12 Feb 2010

Glycotex announces the expansion of patent portfolio in Advanced Wound Healing for GLYC-101

Glycotex, Inc. today announced the expansion of its patent portfolio in Advanced Wound Healing for its product candidate GLYC-101 currently in clinical phase 2 in the United States.

12 Feb 2010

Smart Holograms launches new Verif-EYE bio-optical, interactive visual sensor

Today, Smart Holograms, a UK-Based Technology Company, announced the commercial availability of its new Verif-EYE™ bio-optical, interactive visual sensor that allows consumers to ‘self validate’ their purchases prior to consumption or use to ensure the product is genuine and tamper-free.

12 Feb 2010

Encouraging results from Circassia's ToleroMune ragweed allergy T-cell vaccine phase II clinical trial

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that its ToleroMune(R) ragweed allergy T-cell vaccine achieved positive results in a recently completed phase II clinical trial. Ragweed allergy is particularly common in America, where it affects approximately 25% of the population. Circassia's latest clinical results follow two earlier successful phase II studies with the company's T-cell vaccine against cat allergy.

12 Feb 2010

MITA endorses eight key principles to reduce unnecessary radiation exposure and medical errors

The Medical Imaging & Technology Alliance (MITA), the leading association representing the manufacturers, innovators and developers of medical imaging and radiation therapy systems, today endorsed eight key principles to reduce exposure to unnecessary medical radiation, further minimize medical errors and improve reporting of adverse events.

12 Feb 2010

Formatech issued patent covering novel formulation methods to enhance solubility of certain hydrophobic compounds

Today, Formatech, Inc. announced the issuance of U.S. patent 7,659,310, entitled “Methods of Enhancing Solubility of Agents” which covers novel formulation methods to enhance the solubility of certain hydrophobic compounds.

12 Feb 2010

American Red Cross raises $32M in mobile giving for ongoing relief efforts in Haiti

Hundreds of thousands of cell phone users have made $10 donations to the American Red Cross Haiti Relief and Development Fund by sending the word "Haiti" to 90999, raising a record-shattering $32 million in mobile giving for the ongoing relief efforts.

12 Feb 2010

MCEG and HTMS report examines potential impact of reform on regional health plans

The Managed Care Executive Group and HTMS, with the help of Health Dialog, have jointly released a new report which examines strategic and operational priorities for 2010, as well as the potential impact of reform on regional health plans which composes the majority of the MCEG membership.

12 Feb 2010

IBM, VLSCI scientists to use Blue Gene supercomputer to study human disease

IBM today announced a Research collaboratory in Melbourne, Australia, where scientists from the Victorian Life Sciences Computational Initiative at the University of Melbourne and the IBM Research Computational Biology Center will use high performance computing – including IBM's Blue Gene supercomputer – to study human disease.

12 Feb 2010

Sustamine L-Alanyl-L-Glutamine supplement increases performance in endurance exercise and activity

A clinical study by Dr. Jay Hoffman, PhD, professor and chair of the Department of Health and Exercise Science at the College of New Jersey, has shown Sustamine™ L-Alanyl-L-Glutamine, increases performance in endurance exercise and activity. The study was published on February 3, 2010, in the Journal of the International Society of Sports Nutrition (JISSN), a peer-reviewed journal covering various aspects of sports nutrition, supplementation, exercise metabolism, and/or scientific policies related to sports nutrition.

12 Feb 2010

ASU scientists develop versatile DNA reader to unlock DNA genetic code

Arizona State University scientists have come up with a new twist in their efforts to develop a faster and cheaper way to read the DNA genetic code. They have developed the first, versatile DNA reader that can discriminate between DNA's four core chemical components⎯the key to unlocking the vital code behind human heredity and health.

12 Feb 2010

Proving value a challenge for comparative effectiveness and pharmaceutical technologies

The Wall Street Journal reports that "an examination of one of the best-known examples of a comparative-effectiveness analysis shows how complicated such a seemingly straightforward idea can get" as officials look for savings in the health care system." One study, called Courage, "found that the most common heart surgery -- a $15,000 procedure that unclogs arteries using a small scaffold or stent -- usually yields no additional benefit when used with a cocktail of generic drugs in patients suffering from chronic chest pain."

12 Feb 2010

Siemens Healthcare renews strategic alliance with NextGen Healthcare Information Systems

Today, Siemens Healthcare announced it has renewed its strategic alliance with NextGen Healthcare Information Systems to deliver innovative ambulatory information technology (IT) solutions. More than 35 Siemens customers have already deployed NextGen Healthcare's ambulatory IT tools throughout their physician networks as a result of the relationship, formed to offer healthcare providers interoperable solutions that cross the care coordination gap between the acute and ambulatory environments.

12 Feb 2010

Researchers identify potential drug candidate that halts tumor growth

A novel - and rapid - anti-cancer drug development strategy has resulted in a new drug that stops kidney and pancreatic tumors from growing in mice. Researchers at the Moores Cancer Center at the University of California, San Diego, have found a drug that binds to a molecular "switch" found in cancer cells and cancer-associated blood vessels to keep it in the "off" position.

12 Feb 2010

pSivida reports consolidated net loss of $24,000 for quarter ended December 31, 2009

pSivida Corp. , a drug delivery company with two of the only three ophthalmic sustained release delivery products approved by the FDA for treatment of back-of-the-eye diseases, today announced financial results for its second quarter and six months ended December 31, 2009.

12 Feb 2010

Therapeutic cell types obtained from iPS cells demonstrate abnormal expansion and early cellular aging

Advanced Cell Technology, Inc. or “ACT” reported that a range of therapeutic cell types obtained from induced pluripotent stem (iPS) cells exhibit abnormal expansion and early cellular aging. The research, which appears online (published-ahead-of- print) in the journal STEM CELLS by ACT and its collaborators at Stem International (SCRMI), Harvard Medical School, and the University of Illinois, compares a variety of replacement cell types derived from human iPS cells with their embryonic stem (ES) cell counterparts. The findings support the use of ACT’s single blastomere-derived human embryonic stem cell lines which do not display early aging.

12 Feb 2010

Mesa Laboratories reports fiscal third quarter results

Mesa Laboratories, Inc. today reported sales and earnings for both its fiscal third quarter and nine months ended December 31, 2009.

12 Feb 2010

Technology News and Research

Histone modifications associated with pancreatic cancer development and progression

Gold nanoparticles for cancer treatment

World leaders need to alter their notions on sustainable agriculture to prevent starvation catastrophe

Healthcare thought leaders and experts to meet in MCEG 2010 Annual Forum

Glycotex announces the expansion of patent portfolio in Advanced Wound Healing for GLYC-101

Smart Holograms launches new Verif-EYE bio-optical, interactive visual sensor

Encouraging results from Circassia's ToleroMune ragweed allergy T-cell vaccine phase II clinical trial

MITA endorses eight key principles to reduce unnecessary radiation exposure and medical errors

Formatech issued patent covering novel formulation methods to enhance solubility of certain hydrophobic compounds

American Red Cross raises $32M in mobile giving for ongoing relief efforts in Haiti

MCEG and HTMS report examines potential impact of reform on regional health plans

IBM, VLSCI scientists to use Blue Gene supercomputer to study human disease

Sustamine L-Alanyl-L-Glutamine supplement increases performance in endurance exercise and activity

ASU scientists develop versatile DNA reader to unlock DNA genetic code

Proving value a challenge for comparative effectiveness and pharmaceutical technologies

Siemens Healthcare renews strategic alliance with NextGen Healthcare Information Systems

Researchers identify potential drug candidate that halts tumor growth

pSivida reports consolidated net loss of $24,000 for quarter ended December 31, 2009

Therapeutic cell types obtained from iPS cells demonstrate abnormal expansion and early cellular aging

Mesa Laboratories reports fiscal third quarter results

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News